Abbildung 34: Antihypertensiva- Eigenschaften
Blockade of the renin–angiotensin–aldosterone system (RAAS) is a potent way to reduce hypertension, and the RAAS forms a target for modern antihypertensive therapy.1 Patient compliance with antihypertensive medication is significantly improved if it requires only once-daily administration.2 Increased compliance, coupled with a 24-h efficacy, may be expected to improve patient outcomes. The ideal antihypertensive should also provide round-the-clock activity, especially in the early morning hours when blood pressure increases and cardiovascular events are at their most frequent.3 As with any drug, the therapeutic objectives should be achieved with a minimum of side effects. 1. Weinen W, et al. A review on telmisartan: a novel, long-acting angiotensin II-receptor antagonist. Cardivasc Drug Rev 2000; 18: 127–156. 2. Iskedjian M, et al. Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: evidence from a meta-analysis. Clin Ther 2002; 23: 302–316. 3. Mulcahy D. Circadian variation in cardiovascular events. Blood Press Monit 1998; 3: 29–34.